Oncology

The industry has concentrated its efforts on developing new therapies with few or no competitors.

Demcizumab is a DLL4-targeted lgG2 humanized monoclonal antibody and a potent inhibitor of the Notch pathway.

COA released a statement explaining that it fundamentally opposes home infusion of chemotherapy, cancer immunotherapy, and cancer treatment supportive drugs due to concerns regarding the safety of patients in such an environment.

Medically integrated pharmacies with access to the EMR incorporate this information into the treatment plan.

By mining a vast trove of genetic data, researchers are enhancing physicians’ ability to treat cancer, predict patient outcomes, and determine which treatment will work best for individual patients.

The CLIO trial evaluated olaparib single-agent therapy versus standard-of-care chemotherapy in platinum-sensitive recurrent epithelial ovarian cancer.

The FDA has approved encorafenib in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation after prior therapy.

Consuming a diet high in fiber was linked with a reduced incidence of breast cancer in an evaluation of all relevant studies, according to findings published in CANCER.

Cervical cancer screening rates in Japan were significantly affected in the years following the devastating Great East Japan Earthquake of 2011, suggesting that disasters can affect cervical cancer screening for years.

Cases studies focused on medication reconcilliation for patients with breast cancer.

During this period, 1834 participants developed lung cancer, of whom 290 had COPD and 1544 did not, according to the researchers.

Directions in Pharmacy® is a full-day regional conference for community and health-system pharmacists.

Oncology pharmacists can prevent errors that occur when a patient’s medications include prescription drugs, OTC medications, herbals, and dietary supplements.

The objective of the study was to find whether niraparib improves PFS in patients with newly diagnosed advanced ovarian cancer after first-line (1L) platinum-based chemotherapy (CT).

XMT-1536, a first-in-class antibody-drug conjugate NaPi2B was well tolerated with no dose-limiting toxicities in patients with ovarian cancer and non-small cell lung cancer (NSCLC).

However, the magnitude of the progression-free survival (PFS) benefit is greatest when surgery achieved complete surgical debulking, specifically in the upfront setting.

The objective of the study was to analyze whether niraparib improves PFS in patients with newly diagnosed advanced ovarian cancer after response to first-line platinum-based chemotherapy.

Front-line use of vigil immunotherapy as maintenance in stage 3-4 ovarian cancer was well tolerated and demonstrated relapse-free survival clinical benefit.

A new blood test has detected more than 50 types of cancer as well as their location within the body, according to an international team of researchers led by the Dana-Farber Cancer Institute and the Mayo Clinic.

New research in 5 human cancer cell lines revealed interdependencies between a tumor and its host’s microenvironment.

Pharmacists working collaboratively can make an impact, including for patients with more acute diseases.

Genomic profiles measured through circulating free DNA in the blood of patients with breast cancer may provide a more effective way to treat the disease and track its progression.

Researchers examine how stem cells promote neuronal growth in tissue regeneration and in cancer progression.

The researchers plan to present updated data at the European Society for Medical Oncology Breast Cancer conference in May.

Small cell lung cancer is highly aggressive and fast-growing, typically recurring and progressing rapidly despite the initial response to chemotherapy.

A highlighted session from the ASHP 54th Midyear Clinical Meeting, held December 8-12, 2019, in Las Vegas, Nevada.

New information from the IQVIA “Global Medicine Spending and Usage Trends” report highlights the expected growth of specialty pharmacy spending by 2024.

DCIS is a noninvasive condition in which abnormal cells are found in the lining of a breast duct but have not spread to other tissues in the breast.